Gilead Sciences EuroCharity's RSS for Gilead Sciences en 2010 31st Saturday of October 2020 07:06:06 PM 31st Saturday of October 2020 07:06:06 PM en 2010 Logo European Commission Grants Marketing Authorization for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis 2020-09-28 16:09:39 15638 2010-03-23T15:57:28Z An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences As with all our actions on remdesivir, we approached this with the aim of helping as many patients as possible 2020-09-28 16:09:07 15637 2010-03-23T15:57:28Z Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal Another big bet by Gilead that an innovative tumor-fighting drug can boost its fortunes 2020-09-14 12:09:02 15624 2010-03-23T15:57:28Z Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19 Expands Previous Authorization of Veklury to Treat Hospitalized Patients with COVID-19 Regardless of Oxygen Status 2020-08-31 13:08:00 15594 2010-03-23T15:57:28Z Gilead: U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma Kite Becomes First Company with Multiple Approved CAR T Therapies 2020-07-27 11:07:34 15575 2010-03-23T15:57:28Z